|
|
Article: OncoGenex Reports Response Data from OCX-011 Phase II.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
OncoGenex Technologies Inc. said encouraging data were reported from a Phase II trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer.
Data were presented by the National Cancer Institute of Canada - Clinical Trials Group at the annual meeting of the American Association for Cancer Research in Los Angeles. OGX-011 is designed to specifically inhibit the production of the cell-survival protein clusterin, which is associated with treatment resistance in many cancers and in response to various treatments.
Five of the 15 patients treated showed a partial response, and nine patients showed disease ...